Proactive Investors - Run By Investors For Investors

SomnoMed showcases SomnoDent sleep apnea device at SLEEP 2009

SomnoMed showcases SomnoDent sleep apnea device at SLEEP 2009

Showcasing its SomnoDent™ MAS dental sleep apnea device, SomnoMed (ASX: SOM) has participated at the Annual SLEEP 2009 exhibition in Seattle.  This is the centre point for Dental Sleep Medicine and the Sleep Medicine fraternity worldwide.

SomnoDent™ MAS was featured for a record number of American Association of Dental Sleep Medicine (AADSM) practitioners, with over 600 delegates and the medical conference of Associated Professional Sleep Societies (APSS), which attracted more than 6,000 delegates.

Exhibition activities were focused on the positioning of the SomnoDent MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing. 

The SomnoDent™ MAS dental sleep device consists of two acrylic plates fitted over the upper and low teeth. A patented fin coupling mechanism on the lower arch accurately positions the lower jaw (mandible) a little forward of its natural position.

Ralf Barschow, SomnoMed's CEO said that SLEEP 2009 was a very important strategic investment for SomnoMed and "I am very pleased with the response. It offered an ideal opportunity to present the SomnoDent™ MAS therapeutic option to a broader medical fraternity."

SomnoMed is positioning the SomnoDent™ MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing.

Barschow said SLEEP 2009 "also confirmed our view that there is a significant demand for the SomnoDent MAS therapy for all patients diagnosed and untreated, as well as non-compliant to traditional treatment options, such as surgery or CPAP."

View full SOM profile View Profile

SomnoMed Ltd Timeline

Newswire
May 03 2016

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use